3Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B [ J ]. Hepatol Int, 2008,2 ( 1 ) : 102-110.
4Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B [ J ]. N Engl J Med, 2008,359 (23) : 2442-2455.
5姚光弼.临床肝胆病学[M].第2版.上海:上海科学技术出版社,2011.245-253.
二级参考文献14
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：829
7Lok AS,Lai CL,Leung N,et al. Long-term safety of lamivudine treatmentin patients with chronic hepatitis B[J]. Gastroenterology,2003,125 (6):1714-1722.
8European Association for the Study of the Liver. EASL clinical practiceguidelines : Management of chronic hepatitis B vims infection [J]. J Hepatol,2012,57(1):167-185.
10Si-Ahmed SN, Pradat P’Zoutendijk R,et al. efficacy and tolerance of acombination of tenofovir disoproxil fumarate plus emtricitabine in patientswith chronic hepatitis B : A European multicenter study [J]. Antiviral Res,2011,92(1): 90-95.
